Gitterman Wealth Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-904
Closed -$234K 116
2021
Q4
$234K Buy
904
+124
+16% +$36.3K 0.17% 72
2021
Q3
$300K Buy
+780
New +$288K 0.24% 44

Other funds holding MRNA

Gitterman Wealth Management's MRNA Position: Q1 2022 in Review

Gitterman Wealth Management sold out of Moderna (MRNA) in Q1 2022, closing a stake of 904 shares — an estimated $234K sold.

Gitterman Wealth Management first reported a position in MRNA in Q3 2021 and held it in 2 quarters. The position peaked at $300K in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Gitterman Wealth Management reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Gitterman Wealth Management sold 904 Moderna shares in Q1 2022, an estimated $234K.
  • Gitterman Wealth Management first reported a position in Moderna in Q3 2021 and held it in 2 quarters.
  • Gitterman Wealth Management's Moderna position peaked at $300K in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Gitterman Wealth Management's 13F filing for Q1 2022, filed 12 May 2022.